(Sharecast News) - Avacta Therapeutics provided a second-quarter business update on Wednesday, reporting continued progress in its oncology pipeline and strengthening of its leadership team as it advanced its 'preCISION' drug development strategy.
The AIMt-raded company said its lead programme, 'FAP-Dox', or AVA6000, a preCISION-enabled form of doxorubicin, continued to progress...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE